Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Jun;69(3):221–231. doi: 10.1016/j.curtheres.2008.06.004

Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study

Changsu Han 1,2, David M Marks 2, Chi-Un Pae 2,3,a,b, Bun Hee Lee 1, Young-Hoop Ko 1, Prakash S Masand 2, Ashwin A Patkar 2, In-Kwa Jung 1
PMCID: PMC3969909  PMID: 24692800

Abstract

Background: Forty-eight percent of somatic symptoms encountered in the primary care setting are medically unexplained. Such symptoms have been associated with negative impact on quality of life and with functional impairment.

Objective: The aim of this study was to assess the potential utility and tolerability of paroxetine for the treatment of undifferentiated somatoform disorder (USD), using the 15-item Patient Health Questionnaire (PHQ-15) to assess the severity of somatic symptoms.

Methods: A prospective, open-label, 8-week pilot study of paroxetine was conducted in outpatients with USD. Data were collected at baseline and at weeks 1, 2, 4, and 8. The primary measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire from baseline to end of treatment. A physical examination, electrocardiography, complete blood count, blood chemistry, urinalysis, and pregnancy test (for women of childbearing potential) were performed at baseline and the end of treatment. Vital signs were measured during each visit. Adverse events (AEs) were recorded during the study and included those determined using the Systematic Assessment for Treatment Emergent Events-General Inquiry.

Results: Forty-three Korean patients were screened for the study. Twenty-two patients (13 women, 9 men; mean [SD] age, 37.4 [12.4] years) were enrolled and 20 completed the study; 2 patients were lost to follow-up. The mean total score on the PHQ-15 from baseline to the end of treatment was significantly decreased (17.2 vs 4.3; P = 0.001), as was the mean total BDI score (12.8 vs. 6.3; P < 0.001). Overall, paroxetine was well-tolerated. Nausea and dry mouth were the most commonly reported treatment-emergent AEs (both, 5 [22.7%]); no serious AEs were reported. No abnormal laboratory results were observed.

Conclusion: This open-label pilot study found that paroxetine had potential utility in the treatment of USD and was generally well-tolerated. These results suggest that adequately-powered, double-blind, placebo-controlled trials are warranted to more fully assess the efficacy and safety of paroxetine in the treatment of USD.

Key Words: undifferentiated somatoform disorder, paroxetine, Patient Health Questionnaire, pilot study

Full Text

The Full Text of this article is available as a PDF (594.9 KB).

References

  • 1.Khan AA, Khan A, Harezlak J. Somatic symptoms in primary care: Etiology and outcome. Psychosomatics. 2003;44:471–478. doi: 10.1176/appi.psy.44.6.471. [DOI] [PubMed] [Google Scholar]
  • 2.Katon W Lin E, Von Korff M. Somatization: A spectrum of severity. Am J Psychiatry. 1991;148:34–40. doi: 10.1176/ajp.148.7.A34. [DOI] [PubMed] [Google Scholar]
  • 3.Smith GR, Jr, Monson RA, Ray DC. Patients with multiple unexplained symptoms. Their characteristics, functional health, and health care utilization. Arch Intern Med. 1986;146:69–72. [PubMed] [Google Scholar]
  • 4.Kroenke K. Patients presenting with somatic complaints: Epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res. 2003;12:34–43. doi: 10.1002/mpr.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.O'Malley PG, Jackson JL, Santoro J. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 1999;48:980–990. [PubMed] [Google Scholar]
  • 6.O'Malley PG, Balden E, Tomkins G. Treatment of fibromyalgia with antidepressants: A meta-analysis. J Gen Intern Med. 2000;15:659–666. doi: 10.1046/j.1525-1497.2000.06279.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454. doi: 10.1002/14651858.CD005454.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Tomkins GE, Jackson JL, O'Malley PG. Treatment of chronic headache with antidepressants: A meta-analysis. Am J Med. 2001;111:54–63. doi: 10.1016/s0002-9343(01)00762-8. [DOI] [PubMed] [Google Scholar]
  • 9.Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282:1737–1744. doi: 10.1001/jama.282.18.1737. [DOI] [PubMed] [Google Scholar]
  • 10.American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders—Fourth Edition. American Psychiatric Association Press; Washington, DC: 1994. [Google Scholar]
  • 11.Kroenke K, Spitzer RL, Williams JB. The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258–266. doi: 10.1097/00006842-200203000-00008. [DOI] [PubMed] [Google Scholar]
  • 12.Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
  • 13.Goldberg DP, Blackwell B. Psychiatric illness in general practice. A detailed study using a new method of case identification. Br Med J. 1970;1:439–443. doi: 10.1136/bmj.2.5707.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS. General versus systematic inquiry about emergent clinical events with SAFTEE: Implications for clinical research. J Clin Psychopharmacol. 1992;12:3–10. doi: 10.1097/00001573-199202000-00002. [DOI] [PubMed] [Google Scholar]
  • 15.Kroenke K, Messina N, III, Benattia I. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry. 2006;67:72–80. doi: 10.4088/jcp.v67n0111. [DOI] [PubMed] [Google Scholar]
  • 16.De Wilde J, Spiers R, Mertens C. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand. 1993;87:141–145. doi: 10.1111/j.1600-0447.1993.tb03345.x. [DOI] [PubMed] [Google Scholar]
  • 17.Fabre LF. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry. 1992;53(Suppl):40–43. [PubMed] [Google Scholar]
  • 18.Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol. 1993;13(Suppl 2):18S–22S. doi: 10.1097/00004714-199312002-00003. [DOI] [PubMed] [Google Scholar]
  • 19.Cohn JB, Crowder JE, Wilcox CS, Ryan PJ. A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol Bull. 1990;26:185–189. [PubMed] [Google Scholar]
  • 20.Doraiswamy PM, Varia I, Hellegers C. A randomized controlled trial of paroxetine for noncardiac chest pain. Psychopharmacol Bull. 2006;39:15–24. [PubMed] [Google Scholar]
  • 21.Patkar AA, Masand PS, Krulewicz S. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med. 2007;120:448–454. doi: 10.1016/j.amjmed.2006.06.006. [DOI] [PubMed] [Google Scholar]
  • 22.Creed F, Fernandes L, Guthrie E, for the North of England IBS Research Group The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124:303–317. doi: 10.1053/gast.2003.50055. [DOI] [PubMed] [Google Scholar]
  • 23.Bird H, Broggini M. Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid arthritis: A randomized, double blind, parallel group study. J Rheumatol. 2000;27:2791–2797. [PubMed] [Google Scholar]
  • 24.Masand PS, Narasimhan M, Patkar AA. Paroxetine for somatic pain associated with physical illness: A review. Prim Care Companion J Clin Psychiatry. 2006;8:122–130. doi: 10.4088/pcc.v08n0301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med. 2004;19:813–818. doi: 10.1111/j.1525-1497.2004.30531.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Panerai AE, Monza G, Movilia P. A randomized, within-patient, cross-over, placebocontrolled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand. 1990;82:34–38. doi: 10.1111/j.1600-0404.1990.tb01584.x. [DOI] [PubMed] [Google Scholar]
  • 27.Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: A meta-analysis of 39 placebo-controlled studies. Pain. 1992;49:205–219. doi: 10.1016/0304-3959(92)90144-Z. [DOI] [PubMed] [Google Scholar]
  • 28.GlaxoSmithKline Paxil (paroxetine hydrochloride) Tablets and Oral Suspension: Prescribing information. http://us.gsk.com/products/assets/us_paxil.pdf Accessed June 1, 2008.
  • 29.Feighner JP, Boyer WE. Paroxetine in the treatment of depression: A comparison with imipramine and placebo. J Clin Psychiatry. 1992;53(Suppl):44–47. [PubMed] [Google Scholar]
  • 30.Rickels K, Amsterdam J, Clary C. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. J Clin Psychiatry. 1992;53(Suppl):30–32. [PubMed] [Google Scholar]
  • 31.Cohen J. Statistical Power Analysis for the Behavioral Sciences. L. Erlbaum Associates; Hillsdale, NJ: 1988. pp. 8–14. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES